UC Davis Cell-Biology Professor Paul Knoepfler Tells Washington Post 'It Seems RFK Jr. Stacked the Committee': Academic-Scientist Voice Joins Mainstream-Media Chorus Criticizing PCAC Panel Composition Alongside FDA Career-Staff Briefing Documents Concluding All Seven Peptides Have Insufficient Evidence
Paul Knoepfler, professor at the University of California, Davis, School of Medicine and a widely followed stem-cell and regenerative-medicine researcher, told The Washington Post this week that the FDA's July 23-24 Pharmacy Compounding Advisory Committee panel has been reshaped in a way that raises concerns about the vote. His direct quote: 'It seems RFK Jr. stacked the committee.' Knoepfler's academic-scientist voice joins the growing critic chorus that has developed over the past two weeks around the PCAC review: FDA career-staff briefing documents (June 29-30) concluding none of the seven peptides has sufficient evidence for 503A bulks list eligibility; STAT News' Lizzy Lawrence scoop on the eight new panelists with peptide industry ties; Public Citizen's July 'Outrage of the Month' advocacy position; BioCentury's industry-analyst piece; and mainstream coverage across NBC News, NPR, CNN, PBS NewsHour, and the Associated Press wire syndicated through hundreds of regional outlets. The Knoepfler quote is the clearest single-line summary of the concerns and will likely circulate as the durable framing of the panel-composition question through the July 23 vote.